Fluoxetine for non-arteritic anterior ischemic optic neuropathy: A double-blind, randomized clinical trial
1 Neurology department, Iran University of Medical Sciences (IUMS), Tehran, Iran
2 Ophthalmology research center, Rasool Akram hospital, Nyayesh street, sattarkhan district, Tehran, Iran
3 Radiation Biology Research Center, Department of Epidemiology, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
Research Article
Open Access Research Journal of Biology and Pharmacy, 2022, 05(02), 007–014.
Article DOI: 10.53022/oarjbp.2022.5.2.0051
Publication history:
Received on 28 May 2022; revised on 01 July 2022; accepted on 03 July 2022
Abstract:
Introduction: Fluoxetine raises the levels of BDNF (brain-derived neurotrophic factor). BDNF is known to improve neurogenesis and plasticity, so it seems to improve Anterior Ischemic Optic Neuropathy (AION). The goal of this study was to find out how Fluoxetine affects the clinical outlook of people with AION.
Methods: In this double-blind, placebo-controlled, randomized clinical trial, patients with AION split into two groups: the fluoxetine group (n=50), which took 20 mg of Fluoxetine every day, and the control group (n=50), which took a placebo pill instead. Both groups were followed for six months. Before and after the trial, patients were given clinical and non-clinical evaluations.
Results: 100 people took part in this study and were evaluated. Subjects in the Fluoxetine group had better visual acuity than those in the placebo group. They had lower scores on the LogMAR scale (P: 0.008 and 0.002), better MD parameters of perimetry (P: 0.003 and 0.002), and shorter VEP latencies (P (in 1st minute): 0.001 and 0.001, P (in 15th minute): 0.038 and 0.011. After the trial of Fluoxetine therapy, there were no changes in color vision, Rnfl in all dimensions, PSD parameter of perimetry, or VEP amplitudes (Ps> 0.05.
Conclusion: Fluoxetine showed promise as a therapy for people with AION, and it was safe to use as a treatment option in addition to corticosteroids
Keywords:
Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION); Fluoxetine; Selective Serotonin Reuptake Inhibitor (SSRI); Brain-Derived Neurotrophic Factor (BDNF); Neuro-regeneration
Full text article in PDF:
Copyright information:
Copyright © 2022 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0